Pliant Therapeutics, Inc.
PLRXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Mar 12, 2026 | Piper Sandler | Yasmeen Rahimi | $3.00(+120%) | $1.36 | StreetInsider |
| Mar 3, 2025 | Stifel Nicolaus | $3.00(+117%) | $1.38 | TheFly | |
| Mar 3, 2025 | Leerink Partners | $2.00(+45%) | $1.38 | TheFly | |
| Sep 13, 2024 | H.C. Wainwright | Ed Arce | $38.00(+221%) | $11.84 | StreetInsider |
| Sep 9, 2024 | Leerink Partners | Faisal Khurshid | $33.00(+156%) | $12.87 | TheFly |
| May 23, 2024 | Piper Sandler | Yasmeen Rahimi | $40.00(+189%) | $13.85 | StreetInsider |
| May 7, 2024 | Stifel Nicolaus | Alex Thompson | $32.00(+130%) | $13.91 | StreetInsider |
| May 7, 2024 | Oppenheimer | Jeff Jones | $48.00(+248%) | $13.79 | StreetInsider |
| May 7, 2024 | H.C. Wainwright | Ed Arce | $36.00(+161%) | $13.79 | StreetInsider |
| May 7, 2024 | RBC Capital | Brian Abrahams | $45.00(+226%) | $13.79 | StreetInsider |
| Dec 7, 2022 | J.P. Morgan | $42.00(+144%) | $17.18 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Canaccord Genuity | maintain | Hold | Mar 13, 2026 |
| Piper Sandler | maintain | Overweight | Mar 12, 2026 |
| RBC Capital | maintain | Sector Perform | Nov 7, 2025 |
| JP Morgan | downgrade | Neutral →Underweight | Oct 10, 2025 |
| Piper Sandler | maintain | Overweight | Aug 8, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Mar 18, 2025 |
| RBC Capital | maintain | Sector Perform | Mar 4, 2025 |
| Citigroup | maintain | Neutral | Mar 4, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Mar 4, 2025 |
| Needham | downgrade | Buy →Hold | Mar 4, 2025 |
| Wells Fargo | maintain | Equal Weight | Mar 4, 2025 |
| Leerink Partners | downgrade | Outperform →Market Perform | Mar 3, 2025 |
| Needham | maintain | Buy | Feb 14, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Feb 14, 2025 |
| Citigroup | downgrade | Buy →Neutral | Feb 10, 2025 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Feb 10, 2025 |
| JP Morgan | downgrade | Overweight →Neutral | Feb 10, 2025 |
| RBC Capital | downgrade | Outperform →Sector Perform | Feb 10, 2025 |
| Canaccord Genuity | downgrade | Buy →Hold | Feb 10, 2025 |
| Wells Fargo | downgrade | Overweight →Equal Weight | Feb 10, 2025 |
| Needham | maintain | Buy | Feb 10, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 8, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 13, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 12, 2024 |
| Needham | maintain | Buy | Aug 8, 2024 |
Earnings History
Next report: Mar 17, 2027 · EPS est. $-0.37| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 11, 2026 | $-0.36 | $-0.34 | — | — |
| May 11, 2026 | $-0.32 | $-0.36 | — | — |
| Mar 11, 2026 | $-0.35 | $-0.42 | — | $5.0M |
| Nov 6, 2025 | $-0.43 | $-0.53 | — | — |
| Aug 7, 2025 | $-0.71 | $-0.62 | — | — |
| May 8, 2025 | $-0.92 | $-0.78 | — | — |
| Mar 3, 2025 | $-0.82 | $-0.99 | — | — |
| Nov 7, 2024 | $-0.95 | $-0.99 | — | $83.3K |
News
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced two presentations related to PLN-101095 at the upcoming 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place November 4 - 8, 2026 at the Phoenix Convention Center in Phoenix, Arizona.
Recognized leader in RNAi drug discovery with track record of advancing novel delivery platforms and therapeutics to drive Company's integrin-mediated delivery platform
Features FORTIFY, the ongoing Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2026 taking place in Madrid, Spain from October 23-27, 2026.
Leader in targeted immuno-oncology drug development brings three decades of academic and biopharmaceutical oncology expertise
Pliant Therapeutics (NASDAQ: PLRX - Get Free Report) and Black Diamond Therapeutics (NASDAQ: BDTX - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, valuation and analyst recommendations. Profitability This table compares Pliant Therapeutics
Connor Clark and Lunn Investment Management Ltd. bought a new stake in Pliant Therapeutics, Inc. (NASDAQ: PLRX) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 536,081 shares of the company's stock, valued at approximately $611,000. Connor Clark and Lunn Investment Management
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for PLN-101095, an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins, in combination with pembrolizumab for the potential the treatment of solid tumors that are resistant to immune checkpoint inhibitors (ICIs).
FORTIFY, a Phase 1b indication expansion trial of PLN-101095, experiencing strong enrollment Appointed seasoned oncology drug development leaders Flavia Borellini, Ph.D. and Robert Iannone, M.D.